Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinica...

Nature Reviews Immunology, Published online: 14 July 2026; doi:10.1038/s41577-026-01338-7A preprint by Lunger et al. reports macrophage engineering through constitutively active synthetic cytokine receptors to induce polarization states that are unobtainable with natural cytokine receptors.

Read more about BioEntrepreneurship

A highly conserved motif in human PD-1 but absent in rodent PD-1 is linked to differential inhibitory activity.

In a first-in-human phase 1 trial, HER2-specific CAR macrophages were feasible to manufacture and well tolerated, with no dose-limiting toxicities in patients with HER2-overexpressing solid tumors.

The application period for the 2024 MACS® Imaging Grant program has concluded.  We are honored that so many researchers shared their brilliant ideas with us on…